Overview

* Taysha reports bigger Q3 net loss of $32.7 mln, with increased R&D expenses

* TSHA-102 granted FDA Breakthrough Therapy designation for Rett syndrome

* Company regained full rights to TSHA-102 Rett syndrome program in October

Outlook

* Company plans to dose first patient in REVEAL trial in Q4 2025

* Taysha expects additional patient enrollment at multiple sites this quarter

* Company regained full rights to TSHA-102 program for strategic flexibility

Result Drivers

* Research and Development Expenses -

R&D costs up to

$25.7 mln from $14.9 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.09

Q3 Net -$32.73

Income mln

Q3 $34.02

Operatin mln

g

Expenses

Q3 -$34.02

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Taysha Gene Therapies Inc ( TSHA ) is $9.00, about 50.4% above its November 3 closing price of $4.46

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)